Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
01 Feb 2017 Nature Reviews Clinical Oncology – Year in Review Genitourinary cancers - Haematologic malignancies - Endocrine and neuroendocrine tumours - Sarcomas - Lung and other thoracic tumours - Head and neck cancers
12 Jan 2017 NICE Issues Recommendations for Pembrolizumab in PD-L1-positive Locally Advanced or Metastatic NSCLC After Chemotherapy Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
19 Dec 2016 EMA Recommends to Extend Indications for Pembrolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
16 Dec 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Alectinib for the Treatment of ALK-Positive Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
07 Dec 2016 Durvalumab in Heavily Pretreated EGFR/ALK Wildtype Advanced NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
06 Dec 2016 PFS Significantly Longer With Osimertinib Than With Platinum-Pemetrexed in EGFR T790M-Positive Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
02 Nov 2016 Withdrawal of the Marketing Authorisation Application for Pemetrexed (as ditromethamine) Hospira Lung and other thoracic tumours - Anticancer agents & Biologic therapy
31 Oct 2016 NICE Recommends Osimertinib for Advanced EGFR T790M Mutation-Positive NCSLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Oct 2016 FDA Approves Pembrolizumab for First-Line Treatment of Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
24 Oct 2016 FDA Modifies Indication for Erlotinib in NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
20 Oct 2016 FDA Approves Atezolizumab for Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
10 Oct 2016 ESMO 2016 Press Release: MEK Inhibition in KRAS-mutant NSCLC Did Not Improve Survival Lung and other thoracic tumours
09 Oct 2016 ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung Lung and other thoracic tumours - Anticancer agents & Biologic therapy
09 Oct 2016 ESMO 2016 Press Release: Pembrolizumab New Option for First Line Treatment of Patients with Advanced Lung Cancer and High PD-L1 Expression Lung and other thoracic tumours
09 Oct 2016 ESMO 2016 Press Release: First-line Pembrolizumab Plus Chemotherapy Significantly Improves Outcomes in Advanced NSCLC Lung and other thoracic tumours